Suchergebnisse - "Tannapfel, Andrea"

PubPharm (15)

1

Lasting response by vertical inhibition with cetuximab and trametinib in KRAS-mutated colorectal cancer patient-derived xenografts

enthalten in: Molecular oncology | 2023

von Reissig, T. | Ladigan-Badura, S. | Steinberg, A. | +14

2

Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

enthalten in: Science advances | 2023

von Cameron, D. | Grosser, J. | Ladigan, S. | +22

3

Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 Trial

enthalten in: Clinical chemistry | 2020

von Lueong, S. | Herbst, A. | Liffers, S. | +8

4

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer : The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Modest, D. | Martens, U. | Riera-Knorrenschild, J. | +16

5

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer

enthalten in: Cancer research | 2019

von Weisner, J. | Landel, I. | Reintjes, C. | +28

6

Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer : Results From the AIO 0207 Trial

enthalten in: Clinical colorectal cancer | 2018

von Noepel-Duennebacke, S. | Arnold, D. | Hertel, J. | +4

7

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab : Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Hegewisch-Becker, S. | Nöpel-Dünnebacke, S. | Hinke, A. | +11

8

A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling

enthalten in: Gut | 2016

von Kong, B. | Wu, W. | Cheng, T. | +19

9

Growth rate of late passage sarcoma cells is independent of epigenetic events but dependent on the amount of chromosomal aberrations

enthalten in: Experimental cell research | 2013

von Becerikli, M. | Jacobsen, F. | Rittig, A. | +9

10

Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group

enthalten in: BMC cancer | 2012

von Reinacher-Schick, A. | Schulmann, K. | Modest, D. | +8